TP53 and inflammatory bowel disease: A targeted next-generation sequencing (NGS) study further confirmed frequent TP53 mutations in SECs, even in the absence of dysplasia or carcinoma, suggesting that SEC may represent an early event in the IBD-associated neoplastic sequence.